Angelina Jolie has ovaries, fallopian tubes removed over cancer concerns
the ONA take:
Actress Angelina Jolie announced Tuesday that she underwent surgery to remove her fallopian tubes and ovaries out of fear of a hereditary form of cancer.
Having lost her mother, grandmother, and aunt to cancer, Jolie underwent a double mastectomy 2 years ago over similar concerns. Jolie opted to have her ovaries and fallopian tubes last weeks after a blood test revealed that she may be in the early stages of cancer.
After Jolie underwent the procedure to remove both of her breasts, the pros and cons of preventative measures were pushed into the spotlight, ultimately causing the "Angelina Jolie effect," in which there was an increase in women with genuine concerns about their family history of breast cancer seeking advice from health care professionals. Her announcement could produce the same effect for women concerned about their risk of ovarian cancer.
Further tests showed that the actress was not actually in the early stages of cancer, but she opted for the surgery before of her family history and because she carries the BRCA1 gene mutation that increases her risk of developing ovarian cancer by 50% and breast cancer by 87%.
Actress Angelina Jolie underwent surgery to remove her fallopian tubes and ovaries out of fear of a hereditary form of cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|